Vascular Biogenics Ltd (VBLT)

[davidal66]

Correct. The interim peak can lead to ending the trial/FDA approval if certain numerical/statistical parameters are met. Don't ask me where I learned this, but I read it somewhere on a google patent search. So, if you increase the number of patients 'n' you can increase your chances. That's my guess at least. Another factor maybe the relative flush cash position they have now as contrasted at last year. There not under the same financial pressure as they were in '15.

If this works, we have a possible Intercept pharma situation a few years back when the stock soared on positive interim news with a low float situation. The situation here is more explosive possibly since the 'smart money' is not invested. We have almost no institutional following: the smart money is following Kite/Juno ext.... The lack of institutional following/mutual funds obviously hurts us in the near term. With a decent mutual fund stake, we would be trading with a market cap of 250 million IMHO. But that ain't the case.

But if we can achieve a similar percentage of partial and complete responders as the phase II, all of this will change. I know of no more potential upside in the biotech universe for '17. That doesn't mean I don't realize there is a chance it will flop, but I believe my odds are better here than with Lotto. A lot better.